Navigation Links
Salix Pharmaceuticals Previews Digestive Disease Week 2007

RALEIGH, N.C.--(BUSINESS WIRE)--May 17, 2007 - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that results of 18 investigator-initiated trials related to the Company's products will be presented at Digestive Disease Week(R) 2007, which will be held May 19-24, 2007. Digestive Disease Week is considered the largest and most prestigious meeting in the world for the GI professional. Every year it attracts more than 16,000 physicians, researchers and academics from around the world who desire to stay up-to-date in their respective fields. The meeting is the year's best opportunity to learn about the latest advances in gastroenterology, hepatology, endoscopy and gastrointestinal surgery; prevention, diagnosis and treatment of digestive disorders; and cutting-edge technological advances.


TOPIC                                        LEAD AUTHOR        DATE

---------------------------------------- -------------------- --------


An open label series of rifaximin for     A. Kornbluth, M.D.   May 20

 long term maintenance therapy for

 patients with refractory pouchitis

History of hypothyroidism is associated   E. Lauritano, M.D.   May 20

 to small intestinal bacterial


High dosage rifaximin for the treatment  E. Scarpellini, M.D.  May 20

 of small intestinal overgrowth

High recurrence of small intestinal       E. Lauritano, M.D.   May 20

 bacterial overgrowth after antibiotic

Rifaximin versus systemic antibiotics     M. Gabrelli, M.D.    May 20

 for the treatment of small bowel

 bacterial overgrowth

Small intestinal bacterial overgrowth in   A. Parodi, M.D.     May 20

 acromegalic patients

May breath test be useful in diagnosis     A. Parodi, M.D.     May 20

 of IBS patients? an Italian Study

The oral nonsystemic antibiotic            H. DuPont, M.D.     May 20

 rifaximin prevents symptom recurrence

 in patients with recurrent C.

 difficile-associated diarrhea

Characterization o
f C. difficile strain     Z. Jiang, M.D.     May 20

 isolated from patients with hospital-

 associated diarrhea

The effect of selective intestinal       A. Saveriadis, M.D.   May 20

 decontamination on liver hemodynamics

 in patients with alcohol related

 decompensated cirrhosis

Restless leg syndrome in patients with    L. Weinstock, M.D.   May 21

 irritable bowel disease: response to

 bacterial overgrowth therapy

Small intestinal bacterial overgrowth in  L. Weinstock, M.D.   May 21

 patients with interstitial cystitis and

 gastrointestinal symptoms

Double blind, randomized study to           M. Lukas, M.D.     May 22

 evaluate efficacy and urinary

 excretional rate of two doses of

 rifaximin-EIR in mild to moderate

 active Crohn's disease (GRACE 02 study)

Rifaximin as a steroid-sparing              T. Shah, M.D.      May 23

 medication in the management of

 patients with mild to moderate

 inflammatory bowel disease

Decreasing rates of colectomy despite       M. Issa, M.D.      May 23

 high rates of hospitalization in C.

 difficile infected IBD patients: a

 tertiary referral center experience


Better efficacy of a new 2-liter bowel         L. Clark        May 22

 cleansing preparation in the ascending


Randomised and controlled clinical trial       H. Gruss        May 23

 of polyethylene glycol with

 electrolytes and ascorbic acid in

 comparison to sodium phosphate for

 bowel preparation before colon cancer

 screening colonoscopy


Efficacy and safety of balsalazide for        J. Quiros        May 22

 treatment of pediatric patients with

 mild to moderate ulcerative colitis: A

 randomized double-blind study


In addition, Salix is supporting, through an unrestricted educational grant, two continuing medical education activities in conjunction with DDW this year: -0-

"Navigating the
 Clinical Maze of GI Disorders"

    Faculty Chair

    Gary Lichtenstein, M.D.

    Professor of Medicine

    Director, Center for Inflammatory Bowel Disease

    University of Pennsylvania School of Medicine

"Maximizing Neoplasia Detection during Colonoscopy: Bowel Preparation Technique and Technology" -0-

    Faculty Chair

    Douglas Rex, M.D.

    Chancellor's Professor

    Indiana University - Purdue University

    Professor of Medicine

    Indiana University School of Medicine

    Director of Endoscopy

    Indiana University Hospital

DDW is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases, the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy and the Society for Surgery of the Alimentary Tract, DDW takes place May 19-24, 2007, at the Washington Convention Center, Washington, DC. The meeting showcases approximately 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. For more information, visit

Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix's strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Company's gastroenterology specialty sales and marketing team.

COLAZAL(R) (balsalazide disodium) Capsules 750 mg, is an anti-inflammatory drug approved for the treatment of mildly to moderately active ulcerative colitis. Safety and effectiveness of COLAZAL beyond 12 weeks has not been established. COLAZAL was well tolerated in clinical studi es. In clinical trials, patients reported the following adverse events most frequently: headache (8%); abdominal pain (6%); diarrhea (5%); nausea (5%); vomiting (4%); respiratory infection (4%); and arthralgia (4%). Withdrawal from therapy due to adverse events was comparable to placebo.

XIFAXAN(R) (rifaximin) tablets 200 mg are indicated for the treatment of patients (greater than or equal to 12 years of age) with travelers' diarrhea caused by noninvasive strains of Escherichia coli. XIFAXAN should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than Escherichia coli. XIFAXAN should be discontinued if diarrhea symptoms get worse or persist more than 24-48 hours and alternative antibiotic therapy should be considered. In clinical trials, XIFAXAN was generally well tolerated. The most common side effects (vs. placebo) were flatulence 11.3% (vs. 19.7%), headache 9.7% (vs. 9.2%), abdominal pain 7.2% (vs. 10.1 %) and rectal tenesmus 7.2% (vs. 8.8%).

MOVIPREP(R) (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution) is indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. MOVIPREP should be used with caution in patients using concomitant medications that increase the risk of electrolyte abnormalities such as diuretics or angiotensin converting enzyme (ACE)-inhibitors or in patients with known or suspected hyponatremia. MOVIPREP should also be used with caution in patients with severe ulcerative colitis, ileus, gastrointestinal obstruction or perforation, gastric retention, toxic colitis, or toxic megacolon. In clinical trials, abdominal distension, anal discomfort, thirst, nausea and abdominal pain were some of the most common adverse reactions to MOVIPREP administration. Vomiting occurred less frequently.

Salix also markets OSMOPREP(TM) Tablets (sodium phosphate monobas ic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP), VISICOL(R) Tablets (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous), PEPCID(R) (famotidine) Oral Suspension, DIURIL(R) (chlorothiazide) Oral Suspension, AZASAN(R) (Azathioprine Tablets, USP), ANUSOL-HC(R) (Hydrocortisone Cream, USP) and PROCTOCORT(R) (Hydrocortisone Cream, USP). Balsalazide disodium tablets, granulated mesalamine, SANVAR(R) (600 ug vials vapreotide acetate powder) and Xifaxan are under development for additional indications.

Salix trades on the NASDAQ Market under the ticker symbol "SLXP."

For more information please contact the Company at 919-862-1000 or visit our web site at Information on our web site is not incorporated in our SEC filings.

Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include risks of regulatory review and clinical trials, competition, intellectual property risks, market acceptance for approved products, management of rapid growth and the need to acquire additional products. The reader is referred to the documents that the Company files from time to time with the Securities and Exchange Commission.


Salix Pharmaceuticals, Ltd.
Adam C. Derbyshire, 919-862-1000
Senior Vice President and
Chief Financial Officer
Mike Freeman, 919-862-1000
Executive Director, Investor Relations and
Corporate Communications


Related medicine technology :

1. Salix Pharmaceuticals Announces Positive Top Line Results of Balsalazide Tablets Registration Study
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile app ... struggle to reverse the tide of prescription drug addiction. The ... their medicine intake and stepping down their dosage in a ... launch in December 2017; the first 100,000 people to sign ... at ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/19/2017)... venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound ... ... Jim Bertolina, PhD ... Tom Tefft ... device executive Josh Stopek , PhD, who has led R&D and business development teams ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids ... sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited ... all ages; it is a non-competitive, non-timed event, which is all about having fun ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
Breaking Medicine News(10 mins):